Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non‐hodgkin lymphoma
- 23 July 2002
- Vol. 95 (3), 576-580
- https://doi.org/10.1002/cncr.10699
Abstract
BACKGROUND Central nervous system (CNS) recurrence is almost invariably fatal in patients with aggressive non‐Hodgkin lymphoma (NHL). Although some protocols are intended to prevent CNS disease, the value of CNS prophylaxis in patients with aggressive NHL remains to be determined. METHODS We retrospectively analyzed a cohort of 68 adults with NHL who had been treated uniformly with systemic chemotherapy and had attained complete remission (CR) of disease. Patients ranged in age from 15 to 77 years (median, 56 years). Median follow‐up after CR was 40 months. After CR was attained, 29 patients (Group A) received CNS prophylaxis consisting of four doses of intrathecal methotrexate 10 mg/m2 and hydrocortisone 15 mg/m2 as soon as they could tolerate it. The other 39 patients (Group B) did not receive CNS prophylaxis. RESULTS Although bulky mass (45% vs. 21%, P = 0.03) was more frequent in Group A than in Group B, none of the patients in Group A experienced CNS recurrence (0%), whereas CNS recurrence occurred in six patients in Group B (15%). This difference was significant (P = 0.03). Multivariate logistic regression analysis for CNS recurrence identified no CNS prophylaxis (P = 0.01) and bone marrow involvement (P = 0.02) as independent predictors. Among patients without CNS disease, systemic recurrence occurred in 5 patients in Group A and in 11 patients in Group B (P = 0.12). The 5‐year overall survival rate from CR was 80% in Group A and 58% in Group B (P = 0.05). The 5‐year recurrence‐free survival rate from CR was 85% in Group A and 51% in Group B (P = 0.01). CONCLUSIONS Prophylactic intrathecal methotrexate and hydrocortisone injection reduces the incidence of CNS recurrence following CR in patients with aggressive NHL and improves the chance of long‐term survival. Cancer 2002;95:576–80. © 2002 American Cancer Society. DOI 10.1002/cncr.10699Keywords
This publication has 12 references indexed in Scilit:
- Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patientsAnnals of Oncology, 2000
- Predictive Factors for Central Nervous System Involvement in Non-Hodgkin's Lymphoma: Significance of Very High Serum LDH ConcentrationsLeukemia & Lymphoma, 2000
- Isolated Central Nervous System Relapse in Aggressive Non-Hodgkin's Lymphoma: the Bologna ExperienceLeukemia & Lymphoma, 1999
- Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic LymphomaBlood, 1998
- Central Nervous System Relapse in Non-Hodgkin LymphomaArchives of Neurology, 1997
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Secondary central nervous system involvement by non‐Hodgkin's lymphoma: The risk factorsHematological Oncology, 1990
- Meningeal involvement in non‐Hodgkin's lymphoma: Symptoms, incidence, risk factors and treatmentScandinavian Journal of Haematology, 1985
- The importance of dose intensity in chemotherapy of metastatic breast cancer.Journal of Clinical Oncology, 1984
- National cancer institute sponsored study of classifications of non-hodgkin's lymphomas. Summary and description of a working formulation for clinical usageCancer, 1982